Season 2 (2021-2030)

Respiratory - Small Molecules (9)

Modality Indication Targets Stage Company Project No. Detail
1 Discovery of a ‘First.In.Class’ New Drug for IPF Treatment
Small Molecules Idiopathic pulmonary fibrosis ARPC2 Candidate SapiensBio.Inc RS-2023-00283815
2 Phase I clinical study of SB17170 for the drug development for idiopathic pulmonary fibrosis
Small Molecules Idiopathic pulmonary fibrosis HMGB1 Phase 1 SPARK Biopharma RS-2023-00259223
3 Development of Novel Agents for Idiopathic Pulmonary Fibrosis: Phase 2a Clinical Trial and phase 2b approval of BBT-877, autotaxin inhibitor, in IPF patients
Small Molecules Idiopathic pulmonary fibrosis Autotacxin Phase 2 Bridge Biotherapeutics, Inc. RS-2023-00219938
4 Clinical Trial Development of A Novel Small Molecule Inhibitor for Idiopathic Pulmonary Fibrosis Treatment
Small Molecules IPF Prolyl-tRNA synthetase (PRS) Phase 2 Daewoong Pharmaceutical Co., Ltd. RS-2022-00166689
5 ATB-610: Small molecule developing as a inhaler with reducing toxicity by inhibiting ALK5 selectively for IPF treatment
Small Molecules IPF ALK5 Candidate Autotelic Bio RS-2022-00165740
6 Development of drug candidate against respiratory infection using Foxj1 as a target
Small Molecules Pneumonia Foxj1 Lead Chonnam National University HN21C0513
7 Development of antibodies to induce lung regeneration for the treatment of emphysema
Small Molecules Pulmonary emphysema Robo1 Hit Asan Medical Center HN21C0202
8 Elicitation of lead compounds for the treatment of chronic obstructive pulmonary disease targeting leucotriene B4 receptor BLT2
Small Molecules COPD BLT2 Lead Korea university HN21C0996
9 Study on lead generation for IPF (idiopathic pulmonary fibrosis) drug based on AI platform
Small Molecules IPF CHIT1 Lead INNOVO Therapeutics HN21C0205
BACK